Santen Pharmaceutical (OTCMKTS:SNPHY) Releases FY 2024 Earnings Guidance

Santen Pharmaceutical (OTCMKTS:SNPHY) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.770-0.770 for the period. The company issued revenue guidance of $2.0 billion-$2.0 billion.

Santen Pharmaceutical Stock Down 7.7 %

Shares of OTCMKTS SNPHY opened at $9.05 on Friday. The company has a fifty day moving average price of $10.30 and a 200 day moving average price of $11.30. Santen Pharmaceutical has a 1-year low of $8.95 and a 1-year high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.